European Countries Diverge on Drug Price Policies Amid U.S. Pressure
European nations are taking opposing approaches to pharmaceutical pricing, with the U.K. adopting more industry-friendly policies following pressure from pharma companies and the Trump administration, while Germany is moving toward cost-cutting measures. The divergence reflects broader tensions between controlling healthcare spending and maintaining pharmaceutical innovation incentives across the continent. These policy choices will significantly impact drug accessibility and affordability for European patients and influence global pharmaceutical pricing strategies.
European countries are pursuing divergent strategies on drug pricing as they balance healthcare budget constraints with industry interests. The U.K. has shifted toward more industry-friendly policies and increased medicine spending following pressure campaigns from pharmaceutical companies and the Trump administration. In contrast, Germany, facing growing health budget deficits, is proposing measures to cut spending and increase fees on the pharmaceutical industry. These contrasting approaches reflect different national priorities and fiscal situations, with the U.K. emphasizing spending increases while Germany focuses on cost containment. The divergence also demonstrates the influence of external pressure, particularly from the U.S., on European pharmaceutical policy decisions.
What's missing
The article is behind a paywall and the full details of specific policy proposals in both countries, the nature of the Trump administration's pressure campaign, and the potential impact on drug availability and patient outcomes are not accessible from the provided excerpt.
What different sources said
- STAT NewsCenter
STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices
Related
Multi-Cancer Blood Test Galleri Fails Primary Trial Endpoint
A major clinical trial of Galleri, a blood test designed to detect multiple cancers early, failed to meet its primary goal of reducing late-stage cancer diagnoses when results were announced in February. Multi-cancer early detection (MCED) tests aim to improve survival rates by identifying disease at earlier, more treatable stages. The failure raises questions about the effectiveness of this promising diagnostic approach despite initial scientific enthusiasm.
Study Uses CPAP Data to Measure Social Jet Lag in Sleep Apnea Patients
Researchers analyzed CPAP adherence records from nearly 3,000 obstructive sleep apnea patients to measure social jet lag—the circadian misalignment between work and free days. About 16-21% of patients showed moderate to severe social jet lag, with prevalence highest in younger and middle-aged adults and declining after age 65. The findings suggest CPAP devices could routinely screen for circadian misalignment, potentially identifying patients who need additional behavioral or activity-based interventions.
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.